SCHEMBL4073316

SCHEMBL4073316

Cc1[nH]c(=O)c2cc(Cl)ccc2c1C1CCN(C)CC1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 3/20 0.48
OPRK1 P41145 3/20 0.48
OPRD1 P41143 2/20 0.48
OPRL1 P41146 2/20 0.48
HRH4 Q9H3N8 3/20 0.45
HTR3A P46098 1/20 0.45
PARP1 P09874 2/20 0.42
HTR2A P28223 1/20 0.40
SLC2A1 P11166 1/20 0.40
HRH3 Q9Y5N1 1/20 0.39
DRD4 P21917 1/20 0.39
PLG P00747 1/20 0.39
MCHR1 Q99705 1/20 0.38
CSF1R P07333 1/20 0.38
HTR6 P50406 1/20 0.38
TNKS O95271 1/20 0.38
TNKS2 Q9H2K2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4078373 0.93 OPRM1 (0.47) OPRM1OPRK1OPRD1OPRL1HRH4
SCHEMBL4076737 0.87 TSHR (0.44) OPRM1OPRK1OPRD1OPRL1HRH4
SCHEMBL4072790 0.86 OPRM1 (0.54) OPRM1OPRK1OPRD1OPRL1PARP1
SCHEMBL4070060 0.86 OPRM1 (0.51) OPRM1OPRK1OPRD1OPRL1PARP1
SCHEMBL4074502 0.85 TNKS (0.47) PARP1HTR2APLGHTR6TNKS
SCHEMBL4078132 0.84 PARP1 (0.44) OPRM1OPRK1OPRD1OPRL1PARP1
SCHEMBL4069626 0.84 HTR2A (0.56) OPRM1OPRK1HTR3APARP1HTR2A
SCHEMBL4072256 0.83 OPRM1 (0.50) OPRM1OPRK1OPRD1OPRL1PARP1
SCHEMBL4072310 0.83 OPRM1 (0.47) OPRM1OPRK1OPRD1OPRL1PARP1
SCHEMBL4079232 0.80 PARP1 (0.40) OPRM1OPRK1OPRD1OPRL1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 OPRM1 3587/4885OPRK1 2040/4885OPRD1 3846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.